» Articles » PMID: 22241952

Benefits of Once-daily Therapies in the Treatment of Hypertension

Overview
Publisher Dove Medical Press
Date 2012 Jan 14
PMID 22241952
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

In patients with hypertension, 24-hour blood pressure control is the major therapeutic goal. The number of daily doses is one characteristic of an antihypertensive agent that may affect the adequacy of 24-hour control. One measure of therapeutic coverage is the 24-hour trough-to-peak ratio, which determines the suitability of an agent for once-daily administration. The closer an agent is to a 100% trough-to-peak ratio, the more uniform the 24-hour coverage and therefore blood pressure control. High trough-to-peak ratio, long-acting antihypertensive medications lower blood pressure more gradually, which reduces the likelihood of adverse events attributable to abrupt drug action that occurs with shorter-acting agents. In hypertension, the natural diurnal variation of blood pressure may be altered, including elevated nighttime pressures. An optimal once-daily hypertension therapy would not only lower blood pressure but also normalize any blunted circadian variations in blood pressure. The benefits of once-daily agents with sustained therapeutic coverage may also be explained, in part, by increased patient adherence to simpler regimens as well as lower loss of blood pressure control during virtually inevitable intermittent noncompliance. Studies have demonstrated that once-daily antihypertensive agents have the highest adherence compared with twice-daily or multiple daily doses, including greater adherence to the prescribed timing of doses.

Citing Articles

An assessment of treatment compliance using the Morisky scale-8 tool in adult hypertensive patients of Eastern India.

Kishor R, Kumari S, Prakash R, Chaudhary N, Shyama S, Ahmad S J Family Med Prim Care. 2024; 13(3):924-931.

PMID: 38736807 PMC: 11086791. DOI: 10.4103/jfmpc.jfmpc_1416_23.


Roadmap for the Management of Type 2 Diabetes and Hypertension in the Middle East: Review of the 2022 EVIDENT Summit.

Al Saleh Y, Al Busaidi N, Al Dahi W, Almajnoni M, Mohammed A, Alshali K Adv Ther. 2023; 40(7):2965-2984.

PMID: 37233878 PMC: 10271906. DOI: 10.1007/s12325-023-02529-7.


Suboptimal control status of young hypertensive population.

Shin D, Choi J, Lee H Clin Hypertens. 2023; 29(1):13.

PMID: 37122032 PMC: 10150511. DOI: 10.1186/s40885-023-00237-6.


Single-pill fixed-dose drug combinations to reduce blood pressure: the right pill for the right patient.

Sarzani R, Laureti G, Gezzi A, Spannella F, Giulietti F Ther Adv Chronic Dis. 2022; 13:20406223221102754.

PMID: 35769133 PMC: 9235298. DOI: 10.1177/20406223221102754.


Effect of Amlodipine/Nebivolol combination therapy on central BP and PWV compared to Amlodipine/Valsartan combination therapy.

Sultan E, Rabea H, Elberry A, Mahmoud H Egypt Heart J. 2022; 74(1):15.

PMID: 35286492 PMC: 8921398. DOI: 10.1186/s43044-022-00254-0.


References
1.
Neutel J, Schnaper H, Cheung D, Graettinger W, Weber M . Antihypertensive effects of beta-blockers administered once daily: 24-hour measurements. Am Heart J. 1990; 120(1):166-71. DOI: 10.1016/0002-8703(90)90174-v. View

2.
Schroeder K, Fahey T, Ebrahim S . How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch Intern Med. 2004; 164(7):722-32. DOI: 10.1001/archinte.164.7.722. View

3.
Andrejak M, Genes N, Vaur L, Poncelet P, Clerson P, Carre A . Electronic pill-boxes in the evaluation of antihypertensive treatment compliance: comparison of once daily versus twice daily regimen. Am J Hypertens. 2000; 13(2):184-90. DOI: 10.1016/s0895-7061(99)00175-2. View

4.
White W . Importance of blood pressure control over a 24-hour period. J Manag Care Pharm. 2007; 13(8 Suppl B):34-9. PMC: 10437563. DOI: 10.18553/jmcp.2007.13.s8-b.34. View

5.
Karve S, Cleves M, Helm M, Hudson T, West D, Martin B . Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin. 2009; 25(9):2303-10. DOI: 10.1185/03007990903126833. View